PUBLISHER: The Business Research Company | PRODUCT CODE: 1939172
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939172
Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy in which T-cells are taken from a patient's blood, modified in a laboratory to express a special receptor that recognizes and destroys cancer cells, and then infused back into the patient. These engineered T-cells multiply and persist in the body as living drugs, targeting cancer cells more effectively.
The primary types of chimeric antigen receptor T-cell therapy include monotherapy and combination therapy. Monotherapy involves the use of a single drug for the treatment of a disease. The target antigens include CD19, CD22, and others, and the applications cover acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and others.
Tariffs are impacting the CAR-T therapy market by increasing costs for imported laboratory equipment, cell culture media, and reagents required for manufacturing CAR-T cells. Segments like CD19-targeted and BCMA-targeted therapies are particularly affected, with regions such as North America and Europe facing supply chain challenges due to import duties. While tariffs create higher operational costs and potential delays, they also encourage localized production of reagents and equipment, which can strengthen domestic manufacturing capabilities and reduce long-term dependence on imports.
The car-t therapy market research report is one of a series of new reports from The Business Research Company that provides car-t therapy market statistics, including car-t therapy industry global market size, regional shares, competitors with a car-t therapy market share, detailed car-t therapy market segments, market trends and opportunities, and any further data you may need to thrive in the car-t therapy industry. This car-t therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The car-t therapy market size has grown rapidly in recent years. It will grow from $2.98 billion in 2025 to $3.45 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to limited availability of personalized immunotherapy, high cost of early car-t treatments, dependence on hospital-based cell processing, nascent regulatory frameworks, low patient awareness of car-t therapy.
The car-t therapy market size is expected to see rapid growth in the next few years. It will grow to $6.08 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to technological advancements in t-cell engineering, growing investment in oncology research, expansion of commercial car-t manufacturing facilities, increasing regulatory approvals, rising collaborations between biopharma and academic institutions. Major trends in the forecast period include rising adoption of car-t therapies in hematologic malignancies, development of targeted antigen-specific car-t treatments, increasing use of combination therapy approaches, expansion of clinical trials and research programs, focus on reducing therapy costs and enhancing accessibility.
The rising prevalence of cancer is anticipated to support the expansion of the CAR-T therapy market going forward. The increasing prevalence of cancer refers to the growing number of diagnosed cancer cases within a population over time. This trend has accelerated research efforts and investment in advanced cancer treatments, including cellular immunotherapies, which represent a major advancement in oncology. These therapies are particularly relevant for addressing unmet needs among cancer patients. For example, in July 2024, according to the Australian Institute of Health and Welfare, a government agency in Australia, cancer diagnoses increased from 160,570 in 2022 to 164,694 in 2023, highlighting a continued upward trend nationwide. As a result, the rising prevalence of cancer is contributing to the expansion of the CAR-T therapy market.
Leading companies operating in the CAR-T therapy market are focusing on developing technologically advanced solutions, such as diagnostic tools, to support treatment personalization and improve patient outcomes. Diagnostic tools include instruments, devices, and software used to identify diseases, assess health conditions, and guide treatment planning. For example, in February 2023, Eurofins Viracor, a US-based clinical diagnostic laboratory, launched the ExPeCT Expansion and Persistence of CAR T Assay. This assay enables longitudinal monitoring of CAR T-cell expansion and persistence, providing real-time data to assess therapy effectiveness. It also helps identify patients at risk of treatment failure due to insufficient CAR T-cell dynamics, allowing earlier clinical intervention and improved outcomes in hematological malignancies.
In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired Iveric Bio for $5.9 billion. With this acquisition, Astellas is better positioned to support patients with ocular diseases at high risk of vision loss. The combination of Iveric Bio's ophthalmology expertise and Astellas' global resources presents an opportunity to advance treatments for blinding retinal conditions, including geographic atrophy (GA). The transaction was subject to approval by Iveric Bio's shareholders and other customary closing conditions, including regulatory approvals. Iveric Bio is a US-based biotechnology company.
Major companies operating in the car-t therapy market are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., CARsgen Therapeutics, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune (UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen, AstraZeneca, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Precision BioSciences, Bellicum, GlaxoSmithKline plc
North America was the largest region in the CAR-T therapy market in 2025. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the car-t therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The chimeric antigen receptor -T therapy market includes revenues earned by CAR-T therapy products and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
CAR-T Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses car-t therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for car-t therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The car-t therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.